BMB Reports 2022; 55(9): 453-458  https://doi.org/10.5483/BMBRep.2022.55.9.023
Dysfunctional pancreatic cells differentiated from induced pluripotent stem cells with mitochondrial DNA mutations
Seongjun So1,2, Song Lee3, Yeonmi Lee2, Jongsuk Han2, Soonsuk Kang2, Jiwan Choi2, Bitnara Kim2, Deokhoon Kim4, Hyun-Ju Yoo1, In-Kyong Shim1, Ju-Yun Oh1, Yu-Na Lee1, Song-Cheol Kim1,3,* & Eunju Kang2,*
1Department of Convergence Medicine & Stem Cell Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 2Department of Biomedical Science, College of Life Science and Center for Embryo & Stem Cell Research, CHA Advanced Research Institute, CHA University, Seongnam 13488, 3Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 4Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
Correspondence to: Song-Cheol Kim, Tel: +82-2-3010-3936; Fax: +82-2-474-9027; E-mail: drksc@amc.seoul.kr; Eunju Kang, Tel: +82-31-881-7846; Fax: +82-2-881-7958; E-mail: ekang@cha.ac.kr
Received: February 10, 2022; Revised: March 30, 2022; Accepted: May 4, 2022; Published online: September 30, 2022.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
Diabetes mellitus (DM) is a serious disease in which blood sugar levels rise abnormally because of failed insulin production or decreased insulin sensitivity. Although many studies are being conducted for the treatment or early diagnosis of DM, it is not fully understood how mitochondrial genome (mtDNA) abnormalities appear in patients with DM. Here, we induced iPSCs from fibroblasts, PBMCs, or pancreatic cells of three patients with type 2 DM (T2D) and three patients with non-diabetes counterpart. The mtDNA mutations were detected randomly without any tendency among tissues or patients. In T2D patients, 62% (21/34) of iPSC clones harbored multiple mtDNA mutations, of which 37% were homoplasmy at the 100% mutation level compared to only 8% in non-diabetes. We next selected iPSC clones that were a wild type or carried mutations and differentiated into pancreatic cells. Oxygen consumption rates were significantly lower in cells carrying mutant mtDNA. Additionally, the mutant cells exhibited decreased production of insulin and reduced secretion of insulin in response to glucose. Overall, the results suggest that screening mtDNA mutations in iPSCs from patients with T2D is an essential step before pancreatic cell differentiation for disease modeling or autologous cell therapy.
Keywords: Diabetes, Human induced pluripotent stem cells, Mitochondria, mtDNA mutation, Pancreatic cell differentiation
INTRODUCTION

Diabetes mellitus (DM) is a group of metabolic disorders characterized by high blood sugar levels over a prolonged period (1). Type 2 diabetes (T2D) is the most common form of diabetes, and especially in the elderly, is a serious disease with life-threatening complications (2). T2D is caused by insulin resistance, which prevents skeletal muscle, liver, and adipose tissue from responding to insulin, resulting in elevated blood glucose (3, 4). Additionally, excessive insulin production and hyperglycemia caused by T2D can damage pancreatic cells, leading to the progressive impairment of insulin secretion (5, 6). In the later stages, islet transplantation is the most effective treatment, but a lack of donors limits its large-scale clinical application. To overcome this issue, the use of induced pluripotent stem cells (iPSCs) may be considered (7, 8).

iPSCs can be generated from somatic cells by transducing transcription factors such, as OCT4, SOX2, KLF4, and c-MYC (9). The iPSCs have great potential for use in drug discovery, disease modeling, and cell therapy, because of their ability to proliferate indefinitely and differentiate into various cell types (10). The iPSCs can also be differentiated into pancreatic cells, which are useful for anti-diabetic drug development, diabetic disease modeling, and clinical treatment. However, abnormalities of the genome, such as aneuploidy, sub-chromosomal copy number variations, and single nucleotide variations in iPSCs limit their clinical use (11).

Mitochondria have an independent genome called mitochondrial DNA (mtDNA) (12). The mtDNA is small (16,569 base pairs), but encodes many genes essential for oxidative phosphorylation and cellular energy production (13). Mutations occur in the mtDNA at a rate about 10 to 20 times that of the nuclear genome and cause numerous inherited diseases in humans (14). Because mtDNA is a multi-copy genome, it often represents a heteroplasmic genotype in which both the healthy and the mutated allele are present in the same cell. Mitochondrial dysfunction may have a direct effect on DM because metabolites produced in mitochondrial metabolism act as additive signals regulating insulin secretion (15). Therefore, the presence of mtDNA mutations in iPSCs can be problematic when using iPSC as autologous cell therapy or disease modeling of DM (16).

It has been reported that individual iPSC clones, each derived from a single cell, can carry mtDNA mutations that cause functional abnormalities, which are not generated during reprogramming but are already present in individual parental cells (17). Also, these somatic mutations tend to increase with age, which is associated with accumulated damage or replication errors in mtDNA (18).

In this study, we generated iPSC clones from fibroblasts, PBMCs, or pancreatic cells of patients with T2D and non-diabetes (ND). The iPSC clones were analyzed for the mtDNA mutations. We also selected 2 iPSC clones derived from one patient and differentiated them into pancreatic cells. Oxygen consumption rate, the production of insulin, and glucose-stimulated insulin secretion (GSIS) were measured to investigate the association between mtDNA mutations and the function of differentiated pancreatic cells.

RESULTS

mtDNA mutations in iPSCs derived from patients with type 2 diabetes

We isolated fibroblasts (Fib), PBMCs (Blo), or pancreatic cells (Pan) from three patients with T2D (T2D-1, 2, and 3). Due to limited access to tissue samples, Fib or Pan were not isolated from T2D-1 and T2D-3, respectively. The seven isolated cell lines were induced iPSCs and selected 5 clones from each cell line except for Blo of T2D-3, which were only 4 clones. A total of 34 clones and parental cells were sequenced whole mtDNA by the Illumina Miseq platform.

No mtDNA mutations were detected in parental Fib and Blo in T2D-1, while 4 and 5 mutations were identified in Fib-iPSCs and Blo-iPSCs, respectively (Table 1). Three mutations were in non-syn or rRNA regions, which could affect mitochondrial function. Each 2 iPSC clones from Fib and Blo were not carried mutant mtDNA. Three clones out of 6 were carried 2 or 3 mutations in one iPSC clone. Two clones (clone 1 and clone 5 from Blo) were shared the same mtDNA mutations (mt2613 and mt11002), additionally, clone 5 were carried two more additional mutations (mt10400 and mt16005).

In the T2D-2, only Fib has detected 2 mutations with 3% and 6% heteroplasmy. There was no shared mutation between parental Fib and Fib-iPSCs. Four Fib-iPSC clones out of five were carried mtDNA mutations. Of which, three clones (clones 1, 2, and 3) contained the same mutation (mt14260, Syn) with homoplasmy. Additionally, two clones (clones 1 and 2) were carried additional 2 or 3 mutations with different heteroplasmy (Table 1). This observation was similar to Blo-iPSCs from T2D-1, which was shared the same mutation among iPSC clones and some clones carried additional mutations. All five Blo-iPSC clones from T2D-2 carried mtDNA mutations. Two of them carried high heteroplasmic mutations with no sharing among iPSC clones. Interestingly, no mutation was identified in parental Pan and Pan-iPSCs (Table 1).

No mutation was detected in Blo-iPSCs from T2D-3, even though two mutations were found in parental Blo. One was 50% heteroplasmy (mt10535, ND4L, Syn), which was shared with Pan as 55% heteroplasmy suggesting germline or de novo mtDNA mutation. Two Pan-iPSC clones carried mtDNA mutations, which were not carried in parental Pan. A similar observation was reported previously (17).

mtDNA mutations in iPSCs derived from patients with non-diabetes

We next isolated Fib, Blo, and Pan from 3 patients with ND (ND-1, 2, and 3). Expect Fib and Blo from ND-2, seven cell lines were induced iPSCs. Three to five clones were established in each line. Nine parental cell lines and 30 iPSC clones were analyzed for mtDNA mutations (Table 2).

Three mutations were identified in Fib of ND-1; mt1351, mt10158, and mt15077. Even 45% heteroplasmy in Fib, iPSC clones had no the same mutation indicating any shared mutation with parental cells. Mutation in mt15077 was shared with Blo of the same individual with similar heteroplasmy (14% and 12%), but any iPSC clones were not carried this shared mutation. However, mt14287C>T mutation was shared among iPSC clones from Fib, Blo, and Pan with high frequency, which 12 clones out of 13 clones carried it with 14%-50% heteroplasmy.

There was no shared mutation among parental cells in ND-2. Mt2976G>A with 48% heteroplasmy was identified in Pan, but any iPSC clones had detected the mutation. No mutation was identified in three different parental cells in ND-3. Seven iPSC clones out of 12 carried mtDNA mutations. Mt4298G>A encoded tRNA was shared with two iPSC clones from Pan, which was 83.5% pathogenicity in Mito TIP (https://www.mitomap. org/MITOMAP).

Comparison of mtDNA mutations in iPSCs between patients with T2D and ND

To investigate the difference in the mtDNA mutation pattern in iPSCs between patients with T2D and ND, we compared mtDNA mutations between the two groups. The average number of mtDNA mutations per iPSC clone was not significantly different in ND and T2D (1.2 vs. 0.9, Fig. 1A). Of all T2D-iPSC clones, 61% (21/34) was carried one or more mtDNA mutations, whereas 80% (24/30) in ND-iPSCs (Fig. 1B). Among the total mtDNA mutations identified in T2D-iPSCs, only 43% (13/30) contained less than 50% heteroplasmy and 37% (11/30) with homoplasmy (Fig. 1C). Interestingly, mtDNA mutations with homoplasmy in ND accounted for only 8% (3/29). Comparisons of iPSC clones with mutations revealed a significantly higher average heteroplasmy in T2D (52%) than in ND (34%) (P < 0.05, Fig. 1D). Additionally, the probability of obtaining an iPSC clone with homoplasmic mtDNA mutation in T2D was 24% and ND only 7% (Fig. 1E).

The distribution of mtDNA mutations showed that non-synonymous (non-syn) mutations resulting in changes in amino acid coding were 46% (17/37) in ND and 37% (11/30) in T2D (Fig. 1F). The synonymous (syn) mutations were 46% (17/37) in ND and 33% (10/30) in T2D. For mutations in the RNA region, it was only 8% (3/37) in ND compared to 23% (7/30) in T2D. Mutations in the D-loop, a non-coding region, were found only in T2D (7%, 2/30).

Our results suggest that although mtDNA mutations in iPSCs occur randomly irrespective of the parental cells, more mtDNA mutations with homoplasmy are found in iPSC clones from T2D than in ND.

mtDNA mutations affecting the function of differentiated pancreatic cells

To determine the relationship between mtDNA mutations and pancreatic lineage differentiation, PBMC-derived iPSC (BiPSC) clones were considered because blood is technically and ethically more convenient to obtain compared to other tissues. Among BiPSCs from 3 T2D patients, T2D-2 BiPSC clone 1 was the only BiPSC clone with a non-syn mutation that changed the amino acid sequence, so we selected T2D-2 BiPSCs.

T2D-2 BiPSC clones were differentiated into pancreatic progenitor cells (PPCs) and PPC markers, including PDX1, NGN3, and NKX6.1, were analyzed by qRT-PCR (Fig. 2A). Clone 1 harboring 100% mt6678A>G and 13% mt7970G>A mutations in the non-syn protein-coding region showed low expression of all genes compared to the other clones (P < 0.05). Also, to determine the relationship between amino acid alterations by mtDNA mutation and the expression of PPC-related genes, we examined the expression of each gene according to the sum of the heteroplasmy in the regions of RNA non-syn protein-coding (Fig. 2B). The expression of PPC genes showed a tendency to decrease in the non-syn mutations. Clone 5 showed high gene expression, but it carried 5% mt4703T>C and 100% mt6458C>T mutations in the syn region (Table 1). Therefore, we decided to proceed with further research by selecting clone 1 as mutant and clone 2 carrying only 5% mt874G>A in the rRNA region as wild-type.

To investigates whether the mtDNA mutations affected the function of differentiated pancreatic cells, clones 1 (mutant) and 2 (wild) were differentiated into pancreatic spheroids. There was no difference in the number (381/384 vs. 382/384) and size (77 vs. 80 μm) of the pancreatic spheroids (Fig. 2B). INSULIN, a differentiation marker of pancreatic cells, was observed in both clones 1 and 2 by immunocytochemistry (ICC) (Fig. 2C).

We also investigated mitochondrial respiration function in iPSC clone 1 and clone 2 with a seahorse platform. Clone 1-derived pancreatic cells showed reduced oxygen consumption rates (OCR) compared with clone 2 (Fig. 2D). Basal OCR, maximal respiration, ATP production, and spare respiratory capacity were significantly lower in clone 1 than in clone 2 (P < 0.05).

Next, we investigated the insulin content of pancreatic spheroids to determine the association of mtDNA mutations with insulin production (Fig. 2E). Intracellular insulin was significantly lower in clone 1 than in clone 2 (P < 0.05).

Finally, to examine the effect of mtDNA mutation on the insulin-secreting function of pancreatic cells, glucose-stimulated insulin secretion (GSIS) was induced by the low and high glucose treatment of iPSC-derived pancreatic spheroids (Fig. 2F) (19). Normal pancreatic cells secrete low insulin under low glucose conditions and increase insulin secretion when the glucose concentration increases (20). Clone 1-derived pancreatic spheroids exhibited low levels of insulin secretion at low glucose concentrations but did not increase insulin secretion even when the glucose concentration was increased, whereas clone 2 significantly increased insulin secretion at high glucose concentrations (P < 0.05).

These results indicate that mtDNA mutations could impair mitochondrial respiration capacity and further affect insulin production and insulin-secreting function in differentiated pancreatic cells.

DISCUSSION

It has been reported that iPSC clones derived from the same individual harbored various somatic mtDNA mutations, which were not found in parental cells (17, 21). As a similar result, we also identified several novel mtDNA mutations at high heteroplasmic or homoplasmic levels in iPSC clones. The mutations were not associated with tissue or disease with T2D. However, more homoplasmic mtDNA mutations were found in iPSCs from patients with T2D compared to ND.

Interestingly, some mutations, which were detected in parental cells with high heteroplasmy, were not detected in any iPSCs (ex, 50%-55% heteroplasmy at mt10535T>C in Blo and Pan from T2D-3, 45% at mt1351G>A in Fib from ND-1, and 48% at mt2976G>A in Pan from ND-2). However, other mutations have been identified in several clones with high heteroplasmy even not present in parental cells (mt2613T>C, mt4298G>A, mt11002A>G, 11976A>G, mt12387C>T, mt14260A>G, and mt14268G>T). These findings suggest that mtDNA mutations may be associated with positive or negative iPSC selection during induction or expansion (17).

mtDNA mutations may affect the differentiation of iPSCs into target cells such as neural cells, cardiomyocytes, and fibroblasts (17, 22, 23). Like the mt3243A>G mutation, there are well-known mtDNA mutations that are closely related to diabetes (24), however, to our knowledge, there are no reports of whether somatic mtDNA mutations in iPSCs cause pancreatic cell dysfunction.

Regulating insulin secretion in pancreatic cells is important for glucose homeostasis (25). In patients with diabetes, postprandial glucose-stimulated insulin secretion (GSIS) is insufficient in pancreatic cells, which is characteristic of diabetic pathology (26). Although the molecular mechanisms involved in GSIS are well known, the correlation between mtDNA mutations and GSIS is unclear and requires further exploration.

T2D requires islet transplantation in severe cases, and as shown in the transplant results of Choi et al. (27), it can be seen that 20% of all islet transplant patients were patients with T2D. However, our study revealed that the function of pancreatic cells derived from iPSC harboring mtDNA mutations was dysfunctional. The mitochondrial respiration capacity was decreased and insulin production and secretion were impaired. Given that ATP production is closely related to insulin secretion (28, 29), these results suggest that mtDNA mutations may affect ATP production and impair ATP-dependent insulin secretion.

Taken together, our study suggests that screening the mtDNA is essential before further research for disease modeling and clinical application of iPSCs as autologous cell therapies for diabetes.

MATERIALS AND METHODS

Further detailed information is provided in the Supplementary Information.

ACKNOWLEDGEMENTS

The study was supported by grants from the National Research Foundation of Korea (NRF-2015K1A4A3046807, NRF-2019M3A9H110358211, and NRF-2020M3A9E4036527), Asan Institute for Life Sciences, Korea (2020IP0021 and 2021P0018-1), Ministry of Health and Welfare of Korea (HI16C1559) and Ministry of Trade, Industry & Energy (MOTIE, Korea, Alchemist Project 20012378).

Footnote

CONFLICTS OF INTEREST

The authors have no conflicting interests.

FIGURES
Fig. 1. mtDNA mutations in patients with ND- and T2D-iPSCs. (A) The number of mtDNA mutations in iPSC clones derived from patients with ND and T2D. There were no significant differences between ND and T2D. (B) The proportion of iPSCs with and without mtDNA mutations in ND and T2D. n = the number of iPSC clones. (C) Heteroplasmy proportion of whole mtDNA mutations in iPSCs. The proportion of homoplasmic mutations was only 8% in ND compared to 37% in T2D. N = the number of mtDNA mutations (D) Heteroplasmy distribution of mtDNA mutations found in ND and T2D. The heteroplasmy of mutations found in T2D was higher than that of ND (*P < 0.05). (E) Probability of obtaining iPSCs with homoplasmic mtDNA mutations. iPSC clones with homoplasmy were found with a probability of 7% in ND and 24% in T2D. (F) Distribution of mtDNA mutations in ND and T2D. The ratio of mutations in the RNA region was higher in T2D than in ND (23% vs. 8%). iPSC: induced pluripotent stem cell; mtDNA: mitochondrial DNA; ND: non-diabetes; T2D: type 2 diabetes.
Fig. 2. mtDNA mutations affect the dysfunction of differentiated pancreatic cells. (A) The gene expression of PPC, PDX1, NGN3, and NKX6.1, relative to GAPDH in T2D-2 BiPSCs. All gene expressions in clone 1 were significantly lower compared to other clones (*P < 0.05, 2 biological replicates, 3 technical replicates). (B) PPC-gene expression was inversely proportional to the sum of the heteroplasmy of mtDNA mutations in the positions of change of the amino acid, and RNA. As heteroplasmy increases, the expression of PPC-related genes decreases. (C) Morphology of clones 1 and 2 and pancreatic spheroids derived from them. Clone 1 had 100% mt6678A>G and 13% mt7970G>A mutations in the non-syn protein-coding region and clone 2 had only 5% mt874G>A mutations in the rRNA region. Both clones showed similar spheroid formation. Scale bar = 200 μm. (D) Immunocytochemistry examining the INSULIN (green) expression of pancreatic spheroids. Nuclei were stained with DAPI (blue). Scale bar = 20 μm. (E) Analysis of OCR levels in differentiated pancreatic cells. In clone 1, all OCRs were significantly lower compared with clone 2 (*P < 0.05, 2 biological replicates, and 3 technical replicates). (F) Insulin production in pancreatic spheroids derived from iPSC clones. The insulin in clone 2 was significantly higher than that of clone 1 (*P < 0.05). (G) GSIS analysis of pancreatic spheroids. Clone 2-derived pancreatic spheroids increased the amount of insulin secretion when glucose concentration increased, whereas clone 1 did not (*P < 0.05, 2 biological replicates, 3 technical replicates). PPC: pancreatic progenitor cell; DAPI: 4′,6-diamidino-2-phenylindole; OCR: oxygen consumption rate; GSIS: glucose-stimulated insulin secretion.
TABLES

mtDNA mutations in iPSCs derived from patients with T2D

Subject Cell origin Position Locus Effect Major haplotype Parental cells (%) Individual iPSC clone (%)
1 2 3 4 5
T2D-1
Fib 3315 ND1 Syn G ND A (48) ND ND
5226 ND2 Non-syn G A (100)
9018 ATPase6 Syn T C (39)
12650 ND5 Non-syn T C (56)
Blo 2613 16S rRNA T ND C (100) ND ND C (100)
10400 ND3 Syn T C (100)
11002 ND4 Syn A G (100) C (100)
16005 ATT/P MitoTIP 25.60% T C (7)
16129 ATT/CR Non-coding G A (78)
T2D-2
Fib 5654 A MitoTIP 29.80% T C (13) C (10) ND
5655 A MitoTIP 26.70% T C (3)
6207 COI Non-syn T C (6)
9928 COIII Non-syn A G (11)
11976 ND4 Non-syn A G (64) G (55)
13726 ND5 Non-syn G T (13)
14260 ND6 Syn A G (100) G (100) G (100)
Blo 874 12S rRNA G ND A (5)
2220 16S rRNA A G (8)
4703 ND2 Syn T C (5)
6458 COI Syn C T (100)
6678 COI Non-syn A G (100)
7970 COII Non-syn G A (13)
13312 ND5 Non-syn T C (75)
14900 Cytb Non-syn G A (13)
Pan ND ND ND ND ND ND
T2D-3 Blo 6023 COI Syn A G (2) ND ND ND ND
10535 ND4L Syn T C (50)
Pan 302 CR:HVS2/ Non-coding A ND ND ND C (31)
9591 COIII Non-syn G A (55)
10535 ND4L Syn T C (55)

ND: not detected, Gray block: no iPSC clone, %: heteroplasmy.


mtDNA mutations in iPSCs derived from patients with ND

Subject Cell origin Position Locus Effect Major haplotype Parental cells (%) Individual iPSC clones (%)
1 2 3 4 5
ND-1 Fib 1351 12S rRNA G A (45)
10158 ND3 Non-syn T C (6)
14287 ND6 Syn A T (36) T (44) T (45) T (47) T (39)
15077 Cytb Non-syn G C (14)
Blo 7780 COII Syn A G (78)
13726 ND5 Non-syn G T (7) T (4)
14287 ND6 Syn A T (35) T (44) T (14) T (44)
15077 Cytb Non-syn G A (12)
15773 Cytb Non-syn G A (24)
Pan 9478 COIII Non-syn T ND C (100)
13726 ND5 Non-syn G T (12)
14268 ND6 Syn G T (14) T (100) T (100)
14287 ND6 Syn A T (34) T (50) T (45)
15087 Cytb Non-syn A G (4)
15096 Cytb Non-syn T C (4)
ND-2
Fib 13726 A MitoTIP 29.80% G T (7)
Blo ND
Pan 2976 16S rRNA G A (48) ND
4028 ND1 Non-syn T G (5) G (12) G (5)
6026 COI Syn G C (5)
11379 ND4 Non-syn T C (6)
14343 ND6 Non-syn A A (16) A (23)
ND-3
Fib 3047 16S rRNA G ND A (8)
Blo 13107 ND5 Non-syn A A (40) A (8) A (39)
Pan 4298 I MitoTIP pathogenic (83.50%) G ND A (52) ND A (47)
4713 ND2 ND2:G82TERM G A (74)

ND: not detected, Gray block: no iPSC clone, %: heteroplasmy.


REFERENCES
  1. Mather H, Nisbet JA, Burton G et al (1979) Hypomagnesaemia in diabetes. Arch Med Res 95, 235-242
    Pubmed CrossRef
  2. Caballero AEJAomr (2005) Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res 36, 241-249
    Pubmed CrossRef
  3. Mellitus D (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28, S5-S10
    Pubmed CrossRef
  4. Lebovitz HE (1999) Type 2 diabetes: an overview. Clin Chem 45, 1339-1345
    Pubmed CrossRef
  5. Leahy JL (2005) Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36, 197-209
    Pubmed CrossRef
  6. Robertson RP, Zhou H, Zhang T and Harmon JS (2007) Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes. Cell Biochem Biophys 48, 139-146
    Pubmed CrossRef
  7. Kieffer TJ, Woltjen K, Osafune K, Yabe D and Inagaki N (2018) Beta‐cell replacement strategies for diabetes. J Diabetes Investig 9, 457-463
    Pubmed KoreaMed CrossRef
  8. Suchy F, Yamaguchi T and Nakauchi H (2018) iPSC-derived organs in vivo: challenges and promise. Cell Stem Cell 22, 21-24
    Pubmed CrossRef
  9. Nakagawa M, Koyanagi M, Tanabe K et al (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26, 101-106
    Pubmed CrossRef
  10. Okano H, Nakamura M, Yoshida K et al (2013) Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 112, 523-533
    Pubmed CrossRef
  11. Park J, Lee Y, Shin J et al (2019) Mitochondrial genome mutations in mesenchymal stem cells derived from human dental induced pluripotent stem cells. BMB Rep 52, 689
    Pubmed KoreaMed CrossRef
  12. Reardon W, Pembrey M, Trembath R et al (1992) Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 340, 1376-1379
    Pubmed CrossRef
  13. Park CB and Larsson N-GJJocb (2011) Mitochondrial DNA mutations in disease and aging. J Cell Biol 193, 809-818
    Pubmed KoreaMed CrossRef
  14. Wallace DC (1994) Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci U S A 91, 8739-8746
    Pubmed KoreaMed CrossRef
  15. Maechler P and Wollheim CBJN (2001) Mitochondrial function in normal and diabetic β-cells. Nature 414, 807-812
    Pubmed CrossRef
  16. Ryan CMJNoa (2005) Diabetes, aging, and cognitive decline. Neurobiol Aging 26, 21-25
    Pubmed CrossRef
  17. Kang E, Wang X, Tippner-Hedges R et al (2016) Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. Cell Stem Cell 18, 625-636
    Pubmed CrossRef
  18. Ziada AS, Ignas‐Menzies J, Lu MY et al (2019) Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection. Aging Cell 18, e13018
    Pubmed KoreaMed CrossRef
  19. Plecitá-Hlavatá L, Jabůrek M, Holendová B et al (2020) Glucose-stimulated insulin secretion fundamentally requires H2O2 signaling by NADPH oxidase 4. Diabetes 69, 1341-1354
    Pubmed CrossRef
  20. MacDonald PE, El-kholy W, Riedel MJ, Salapatek AMF, Light PE and Wheeler MB (2002) The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51, S434-S442
    Pubmed CrossRef
  21. Ma H, Folmes CD, Wu J et al (2015) Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature 524, 234-238
    Pubmed CrossRef
  22. Li S, Pan H, Tan C et al (2018) Mitochondrial dysfunctions contribute to hypertrophic cardiomyopathy in patient iPSC-derived cardiomyocytes with MT-RNR2 mutation. Stem Cell Rep 10, 808-821
    Pubmed KoreaMed CrossRef
  23. Hatakeyama H and Goto Y (2016) Concise review: heteroplasmic mitochondrial DNA mutations and mitochondrial diseases: toward iPSC-based disease modeling, drug discovery, and regenerative therapeutics. Stem Cells 34, 801-808
    Pubmed CrossRef
  24. Suzuki Y, Muramatsu T, Taniyama M et al (1996) Mitochondrial aldehyde dehydrogenase in diabetes associated with mitochondrial tRNALeu (UUR) mutation at position 3243. Diabetes Care 19, 1423-1425
    Pubmed CrossRef
  25. Rorsman P and Braun MJArop (2013) Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol 75, 155-179
    Pubmed CrossRef
  26. Kristinsson H, Smith DM, Bergsten P and Sargsyan EJE (2013) FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinology 154, 4078-4088
    Pubmed CrossRef
  27. Choi JY, Jung JH, Shin S, Kim YH and Han DJJPO (2017) Association between the pancreas transplantation and survival of patients with diabetes: a single center experience. PLoS One 12, e0186827
    Pubmed KoreaMed CrossRef
  28. Shepherd RK, Checcarelli N, Naini A, De Vivo DC, DiMauro S and Sue CM (2006) Measurement of ATP production in mitochondrial disorders. J Inherit Metab Dis 29, 86-91
    Pubmed CrossRef
  29. Kennedy ED, Maechler P and Wollheim CB (1998) Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes 47, 374-380
    Pubmed CrossRef


This Article


Cited By Articles
  • CrossRef (0)

Author ORCID Information

Funding Information

Collections

Services
Social Network Service

e-submission

Archives